AEGON Asset Management (UK)’s Alnylam Pharmaceuticals ALNY Stock Holding History

AEGON Asset Management (UK)’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2K	Hold	9	–	–	﹤0.01%	160
2023 Q1	$2K	Sell	9 -3	-25%	-$631	﹤0.01%	160
2022 Q4	$3K	Hold	12	–	–	﹤0.01%	160
2022 Q3	$2K	Hold	12	–	–	﹤0.01%	161
2022 Q2	$2K	Buy	+12	New	+$1.7K	﹤0.01%	170

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AEGON Asset Management (UK)'s ALNY Position: Q2 2023 in Review

AEGON Asset Management (UK) held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2023 at 9 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #160.

AEGON Asset Management (UK) first reported a position in ALNY in Q2 2022 and has held it in 5 quarters since. The position peaked at $3K in Q4 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

AEGON Asset Management (UK) held 9 shares of Alnylam Pharmaceuticals worth $2K as of Q2 2023.
AEGON Asset Management (UK) left its Alnylam Pharmaceuticals share count unchanged in Q2 2023.
Alnylam Pharmaceuticals made up ﹤0.01% of AEGON Asset Management (UK)'s portfolio in Q2 2023, its #160 holding.
AEGON Asset Management (UK) first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 5 quarters since.
AEGON Asset Management (UK)'s Alnylam Pharmaceuticals position peaked at $3K in Q4 2022.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on AEGON Asset Management (UK)'s 13F filing for Q2 2023, filed 28 Jul 2023.